|
Jul 23
|
Looking Back to the Future: Gilead's Long-Standing Commitment To Help End the HIV Epidemic
|
|
Jul 23
|
What to Expect From Gilead Sciences’ Q2 2025 Earnings Report
|
|
Jul 19
|
Why Gilead Sciences (GILD) Appeals to Income Investors in the Pharma Sector
|
|
Jul 18
|
HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock
|
|
Jul 18
|
Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?
|
|
Jul 17
|
GSK’s Linerixibat Poised to Address Substantial Unmet Need for the Treatment of Pruritus Associated with Primary Biliary Cholangitis, According to Spherix Global Insights
|
|
Jul 17
|
Human Immunodeficiency Virus (HIV) 7MM Drug Forecast and Analysis Report 2023-2033 | Market to Reach $32.1 Billion - Gilead Sciences to Remain the Leading Player
|
|
Jul 14
|
WHO endorses Gilead’s Yeztugo for HIV prevention
|
|
Jul 14
|
Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025
|
|
Jul 14
|
Biotech Stocks Are Ready to Rebound. Gilead Sciences and 2 More to Watch Now.
|
|
Jul 11
|
Sector Update: Health Care Stocks Retreat Late Afternoon
|
|
Jul 11
|
Equity Markets Lower After US Treasury Budget Surplus in June
|
|
Jul 11
|
Guardant Health, Gilead Sciences, Inspire Medical Systems, Enovis, and AMN Healthcare Services Stocks Trade Down, What You Need To Know
|
|
Jul 10
|
Gilead Sciences, Inc. (GILD): A Bull Case Theory
|
|
Jul 10
|
Here's Why Gilead Sciences (GILD) is a Strong Momentum Stock
|
|
Jul 10
|
Morgan Stanley Assumes Coverage of Kymera Therapeutics (KYMR) Stock with Overweight Rating
|
|
Jul 9
|
AHF: Gilead’s Greed Costs Latin America HIV Protection
|
|
Jul 9
|
Gilead Sciences (NasdaqGS:GILD) Partners With Global Fund To Supply HIV Prevention Drug
|
|
Jul 9
|
Gilead Sciences, Inc. (GILD) Reports Advances in HIV Treatment with Phase 2/3 Clinical Trial Update
|
|
Jul 9
|
$14 Billion Cell and Gene Therapy Market to Double by 2030, Driven by Oncology and RNA Breakthroughs, reports Kalorama Information
|